Company Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases.
Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors.
The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors.
In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection.
Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH.
The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021.
Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Sep 28, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 231 |
| CEO | Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D. |
Contact Details
Address: 5959 Horton Street, Suite 300 Emeryville, California 94608 United States | |
| Phone | (510) 871-6100 |
| Website | gritstonebio.com |
Stock Details
| Ticker Symbol | GRTS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001656634 |
| CUSIP Number | 39868T105 |
| ISIN Number | US39868T1051 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Erin E. Jones M.S. | Executive Vice President and Chief Operating Officer |
| Dr. Karin Jooss Ph.D. | Executive Vice President and Head of Research and Development |
| Vassiliki Economides | Executive Vice President and Chief Financial Officer |
| James Cho | Chief Accounting Officer |
| George MacDougall | Director of Investor Relations and Corporate Communications |
| Stacy Proctor | Executive Vice President and Chief People Officer |
| Dr. Matthew J. Hawryluk M.B.A., Ph.D. | Executive Vice President and Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2024 | 8-K | Current Report |
| Apr 2, 2024 | 424B5 | Filing |
| Apr 1, 2024 | 424B5 | Filing |
| Apr 1, 2024 | 8-K | Current Report |
| Mar 5, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 5, 2024 | 8-K | Current Report |
| Mar 5, 2024 | 10-K | Annual Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |